Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9789508 | 0.95 | EPHX2 (0.56) | LMNATSHREPHX2PKMADRA1A | |
| SCHEMBL599560 | 0.95 | EPHX2 (0.56) | LMNATSHREPHX2PKMADRA1A | |
| SCHEMBL8576664 | 0.95 | EPHX2 (0.56) | LMNATSHREPHX2PKMADRA1A | |
| SCHEMBL10137837 | 0.95 | LMNA (0.50) | LMNATSHREPHX2PKMADRA1A | |
| SCHEMBL13688469 | 0.91 | ALDH1A1 (0.50) | LMNATSHREPHX2PKMADRA1A | |
| SCHEMBL21675625 | 0.89 | KDM4C (0.50) | LMNAEPHX2PKMADRA1AHPGD | |
| SCHEMBL24818366 | 0.87 | NAMPT (0.52) | LMNATSHREPHX2PKMHPGD | |
| SCHEMBL10660707 | 0.87 | NAMPT (0.52) | LMNATSHREPHX2PKMHPGD | |
| SCHEMBL10345306 | 0.87 | NAMPT (0.52) | LMNATSHREPHX2PKMHPGD | |
| SCHEMBL10345059 | 0.87 | NAMPT (0.52) | LMNATSHREPHX2PKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067650-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11691997-B2 | Macrocycles | LUMIPHORE, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210290787-A1 | MACROCYCLE CONJUGATES | LUMIPHORE, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20200405887-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2020-12-31 | — | — | US | disclosed |
| US-20200062757-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | LUMIPHORE, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-10352938-B2 | Macrocyclic HOPO chelators | LUMIPHORE, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10273256-B2 | Macrocycles | LUMIPHORE, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-10239878-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | LUMIPHORE, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180194766-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2017-12-21 | — | — | US | disclosed |
| EP-2423201-B1 | Luminescent macrocyclic lanthanide complexes | UNIV CALIFORNIA (US) | 2017-10-04 | — | — | EP | disclosed |
| US-20170183365-A1 | MACROCYCLES | LUMIPHORE, INC. | 2017-06-29 | — | — | US | disclosed |
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290787-A1 | MACROCYCLE CONJUGATES | FOLH1, KLK3, CD47 | LMNA 3776/4885TSHR 3436/4885EPHX2 2132/4885 |
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | CLTB, CLTA, EPCAM | LMNA 1626/4885TSHR 804/4885EPHX2 3366/4885 |
| US-20200062757-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | LMNA 3330/4885TSHR 477/4885EPHX2 4151/4885 |
| US-11691997-B2 | Macrocycles | HCCS, ABCB7, AURKAIP1 | LMNA 3079/4885TSHR 1004/4885EPHX2 2440/4885 |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | LMNA 3429/4885TSHR 4691/4885EPHX2 2646/4885 |
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | CLTB, CLTA, EPCAM | LMNA 1626/4885TSHR 804/4885EPHX2 3366/4885 |
| US-20240067650-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | LMNA 3330/4885TSHR 477/4885EPHX2 4151/4885 |
| US-20180194766-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | LMNA 3330/4885TSHR 477/4885EPHX2 4151/4885 |
| US-10273256-B2 | Macrocycles | HCCS, ABCB7, AURKAIP1 | LMNA 3079/4885TSHR 1004/4885EPHX2 2440/4885 |
| US-20170183365-A1 | MACROCYCLES | HCCS, ABCB7, AURKAIP1 | LMNA 3079/4885TSHR 1004/4885EPHX2 2440/4885 |
| US-10239878-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | TFRC, CLTC, SLC39A3 | LMNA 3330/4885TSHR 477/4885EPHX2 4151/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | LMNA 3429/4885TSHR 4691/4885EPHX2 2646/4885 |
| US-20200405887-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | LMNA 3330/4885TSHR 477/4885EPHX2 4151/4885 |
| US-10352938-B2 | Macrocyclic HOPO chelators | PHPT1, SSB, CD69 | LMNA 3821/4885TSHR 284/4885EPHX2 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.